Celldex Therapeutics, Inc.
CLDXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCelldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases. With a market capitalization of $3.12B, it sits in mid-cap territory. The company's drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate.
Market Cap
$3.12B
Beta
0.84
P/E (TTM)
—
P/E (Fwd)
-9.44
EPS (TTM)
$-4.35
EPS (Fwd)
$-4.21
ROE
-43.9%
ROA
-27.6%
Cash
$717.6M
Total Debt
$4.9M
Free CF
-$133.1M
52W Change
63.3%
Annual Financials
Cash vs Debt
Where CLDX stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, CLDX finished 19.53% above its 150-day moving average ($33.03) and 25.65% above its 200-day moving average ($31.42). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CLDX overbought or oversold?
At the September 3, 2026 close, CLDX's RSI(14) was 28.2, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Celldex Therapeutics, Inc. holds $717.6M in cash against $4.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$133.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -43.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been uneven over recent years, ranging from $2.4M to $1.5M.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing CLDX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.